Compare BNC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNC | DCTH |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.8M | 289.2M |
| IPO Year | N/A | N/A |
| Metric | BNC | DCTH |
|---|---|---|
| Price | $7.02 | $10.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 688.8K | ★ 739.3K |
| Earning Date | 12-23-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $4,027,431.00 | ★ $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | ★ N/A | $300.67 |
| Revenue Growth | 27.46 | ★ 251.54 |
| 52 Week Low | $4.65 | $8.12 |
| 52 Week High | $82.88 | $18.23 |
| Indicator | BNC | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 62.85 |
| Support Level | $6.65 | $9.59 |
| Resistance Level | $7.72 | $10.14 |
| Average True Range (ATR) | 0.59 | 0.44 |
| MACD | 0.22 | 0.16 |
| Stochastic Oscillator | 72.94 | 87.15 |
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.